What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Cagrilintide + Semaglutide combination
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating CagriSema through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
CagriSema is the fixed-combination presentation pairing the long-acting amylin analogue Cagrilintide with the GLP-1 receptor agonist Semaglutide, sitting in Phase 3 development inside Novo Nordisk's REDEFINE program for chronic weight management. It represents the next generation of GLP-1-anchored weight pharmacology: layering an amylin-axis mechanism (acting on the area postrema and across the calcitonin-receptor family) over the established GLP-1 receptor mechanism. Because the two signalling pathways are anatomically separate and pharmacologically distinct, the combined dose produces additive weight-reduction effects beyond what maximal-dose Semaglutide monotherapy delivers in dose-equivalent comparisons. The catalogue default ratio is 1:1 by mass of Cagrilintide to Semaglutide; non-standard ratios are available for research workflows characterising ratio-dependent biology. For compounding pharmacy buyers, Vialdyne releases CagriSema as a pre-blended co-lyophilised vial against a ≥99.0% main-peak HPLC specification per component. The batch is released against a documented in-vial ratio rather than total mass alone. Co-lyophilisation is the right method here, not solution-phase mixing inside the cleanroom: amylin-class peptides have a well-documented surface-aggregation sensitivity in dilute aqueous solution, and the co-lyophilised cake locks the ratio at the freeze-drying step before that aggregation window opens. The released-batch COA certifies both component purities individually plus the actual ratio inside the vial (typically within ±5% of nominal). Three fill strengths, 5, 10, and 20 mg total, cover bench-scale and compounding-pharmacy dispensing workflows.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for CagriSema, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →CagriSema
VD260428-CS20039 · 99.17%
VerifiedRequest full COA →CagriSema
VD260428-CS5043 · 99.12%
VerifiedRequest full COA →CagriSema
VD260428-CS10044 · 99.03%
Regulatory note
Supplied as a combination product still under investigation via Novo Nordisk's REDEFINE program; as of this writing it holds no approval as a finished drug. Each batch ships with component-level analytical data and a verified ratio.
Selected literature
Frequently asked questions
Amylin-class peptides, Cagrilintide included, have a documented sensitivity to surface-mediated aggregation when held in dilute aqueous solution, the same physical chemistry that drives native amylin to form fibrils in the pancreatic islet under disease conditions. Co-lyophilising Cagrilintide with Semaglutide produces a stable solid-state cake where the ratio is locked in at the freeze-drying step and surface-aggregation effects don't manifest until reconstitution at point of use. Solution-phase mixing of separately-purchased vials is operationally possible but produces variable ratios and progressive amylin-component degradation over time. The pre-blended product also collapses the documentation chain: a single COA certifies both component purities and the verified in-vial ratio, simplifying the receiving pharmacy's QA file.
Two distinct signalling axes converge on the same clinical endpoint. Cagrilintide binds at the amylin / calcitonin-receptor family in the area postrema, where it contributes to satiety signalling and gastric-emptying delay. Semaglutide binds at the GLP-1 receptor across the arcuate nucleus and peripheral tissue beds, where it contributes appetite suppression and insulinotropic effects. Because the two signalling cascades reinforce rather than compete, layering them produces additive weight-reduction effects beyond what either monotherapy reaches at its own ceiling dose. The clinical-program rationale, validated in the Phase 2 REDEFINE-2 readouts, is that the combination delivers larger weight-reduction signals than maximal-dose Semaglutide monotherapy.
Related peptides
